Drug-Eluting Versus Bare-Metal Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction

JACC: Cardiovascular Interventions

Volumn 1, Issue 2, 2008, Pages 129-135

  Hannan, Edward L ^a   Racz, Michael ^b   Walford, Gary ^c   Holmes, David R ^d   Jones, Robert H ^e   Sharma, Samin ^f   Katz, Stanley ^g   King III, Spencer B ^h  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^c St Joseph's Hospital   (United States)

^d MAYO CLINIC   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f MOUNT SINAI MEDICAL CENTER   (United States)

^g North Shore LIJ Health System ^*  (United States)

^h PIEDMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; PACLITAXEL; RAPAMYCIN;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BARE METAL STENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY BYPASS SURGERY; DISEASE SEVERITY; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; ST SEGMENT ELEVATION; STENT; SURGICAL MORTALITY;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CORONARY ARTERY BYPASS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; METALS; MIDDLE AGED; MYOCARDIAL INFARCTION; NEW YORK; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; REGISTRIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SIROLIMUS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 41949125911     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2008.01.006     Document Type: Article

References (35)

1. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
2. Holmes Jr. D.R., Leon M.B., Moses J.W., et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109 (2004) 634-640
3. Stone G.W., Ellis S.G., Cox D.A., et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109 (2004) 1942-1947
4. Colombo A., Drzewiecki J., Banning A., et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stent for coronary arteries. Circulation 108 (2003) 788-794
5. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
6. Stone G.W., Ellis S.G., Cannon L., et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 294 (2005) 1215-1223
7. Ardissino D., Cavallini C., Bramucci E., et al. Sirolimus-eluting stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 292 (2004) 2727-2734
8. Hermiller J.B., Raizner A., Cannon L., et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS trial. J Am Coll Cardiol 45 (2005) 1206-1212
9. Grube E., Silber S., Hauptmann K.E., et al. TAXUS I: six- and 12-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107 (2003) 38-42
10. Katritsis D.G., Karvouni E., and Ionnidis J.P. Meta-analysis comparing drug-eluting stents with bare-metal stents. Am J Cardiol 95 (2005) 640-643
11. Indolfi C., Pavia M., and Angelillo I.F. Drug-eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis). Am J Cardiol 95 (2005) 1146-1152
12. Ong A.T., Aoki J., van Mieghem C.A., et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 45 (2005) 947-953
13. Bavry A.A., Kumbhani D.J., Helton T.J., and Bhatt D.L. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary interventions?. A meta-analysis. J Am Coll Cardiol 45 (2005) 941-946
14. Regar E., Serruys P.W., Bode C., et al. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting BX Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 106 (2002) 1949-1956
15. Tanabe K., Serruys P.W., Grube E., et al. TAXUS III trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 107 (2003) 559-564
16. Bavry A.A., Kumbhani D.J., Helton T.J., Borek P.P., Mood G.R., and Bhatt D.L. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 119 (2006) 1056-1061
17. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
18. Shuchman M. Trading restenosis for thrombosis?. New questions about drug-eluting stents. N Engl J Med 355 (2006) 1949-1952
19. Lagerqvist B., James S.K., Stenestrand Ulindback J., Nilsson T., Wallentin L., and SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
20. U.S. Food and Drug Administraciton. CYPHER™ Sirolimus-eluting Coronary Stent on RAPTOR® Over-the-Wire Delivery System or RAPTORRAIL® Rapid Exchange Delivery System - P020026. http://www.fda.gov/cdrh/PDF2/P020026.html Accessed September 4, 2007
21. U.S. Food and Drug Administration. TAXUS™ Express 2™ Paclitaxel-Eluting Coronary Stent System (Monorail and Over-the-Wire) - P030025 Name. http://www.fda.gov/cdrh/PDF3/P030025.html Accessed September 4, 2007
22. Spaulding C., Henry P., Teiger E., et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 (2006) 1093-1104
23. Menichelli M., Parma A., Pucci E., et al. Randomized trial of sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction. J Am Coll Cardiol 49 (2007) 1924-1930
24. Laarman G.J., Suttorp M.J., Dirksen M.T., et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary interventions. N Engl J Med 355 (2006) 1105-1113
25. Anderson H.V., Smalling R.W., and Henry T.D. Drug-eluting stents for acute myocardial infarction. J Am Coll Cardiol 49 (2007) 1931-1933
26. Lin D.Y., and Wei L.J. The robust inference for the proportional hazards model. J Am Stat Assoc 84 (1989) 1074-1078
27. Allison P. Survival Analysis Using the SAS System: A Practical Guide (1995), SAS Institute Inc, Cary, NC
28. Ghali W.A., Quan H., Brant R., et al. Comparison of two methods for calculating adjusted survival curves from proportional hazards. JAMA 286 (2001) 1494-1497
29. Rosenbaum P.R., and Rubin D.R. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 79 (1984) 516-524
30. Rosenbaum P.R., and Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 70 (1983) 41-55
31. U.S. Food and Drug Administration. Update to FDA statement on coronary drug-eluting stents. http://fda.gov/cdrh/news/010407.html Accessed September 4, 2007
32. Win H.K., Caldera A.E., Maresh K., et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297 (2007) 2001-2009
33. Beohar N., Davidson C.J., Kip K.E., et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 297 (2007) 1992-2000
34. Pasceri V., Patti G., Speciale G., Pristipino C., Richichi G., and Di Sciascio G. Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am Heart J 153 (2007) 749-754
35. Hannan E.L., Racz M.J., McCallister B.D., et al. A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 33 (1999) 63-72